Literature DB >> 29656380

Trends in use of lymphadenectomy in surgery with curative intent for intrahepatic cholangiocarcinoma.

X-F Zhang1,2, J Chakedis2, F Bagante3, Q Chen2, E W Beal2, Y Lv1, M Weiss4, I Popescu5, H P Marques6, L Aldrighetti7, S K Maithel8, C Pulitano9, T W Bauer10, F Shen11, G A Poultsides12, O Soubrane13, G Martel14, B Groot Koerkamp15, A Guglielmi3, E Itaru16, T M Pawlik2.   

Abstract

BACKGROUND: The role of routine lymph node dissection (LND) in the surgical treatment of intrahepatic cholangiocarcinoma (ICC) remains controversial. The objective of this study was to investigate the trends of LND use in the surgical treatment of ICC.
METHODS: Patients undergoing curative intent resection for ICC in 2000-2015 were identified from an international multi-institutional database. Use of lymphadenectomy was evaluated over time and by geographical region (West versus East); LND use and final nodal status were analysed relative to AJCC T categories.
RESULTS: Among the 1084 patients identified, half (535, 49·4 per cent) underwent concomitant hepatic resection and LND. Between 2000 and 2015, the proportion of patients undergoing LND for ICC nearly doubled: 44·4 per cent in 2000 versus 81·5 per cent in 2015 (P < 0·001). Use of LND increased over time among both Eastern and Western centres. The odds of LND was associated with the time period of surgery and the extent of the tumour/T status (referent T1a: OR 2·43 for T2, P = 0·001; OR 2·13 for T3, P = 0·016). Among the 535 patients who had LND, lymph node metastasis (LNM) was noted in 209 (39·1 per cent). Specifically, the incidence of LNM was 24 per cent in T1a disease, 22 per cent in T1b, 42·9 per cent in T2, 48 per cent in T3 and 66 per cent in T4 (P < 0·001). AJCC T3 and T4 categories, harvesting of six or more lymph nodes, and presence of satellite lesions were independently associated with LNM.
CONCLUSION: The rate of LNM was high across all T categories, with one in five patients with T1 disease having nodal metastasis. The trend in increased use of LND suggests a growing adoption of AJCC recommendations in the treatment of ICC.
© 2018 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2018        PMID: 29656380     DOI: 10.1002/bjs.10827

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  16 in total

1.  Trends in the Incidence, Treatment and Outcomes of Patients with Intrahepatic Cholangiocarcinoma in the USA: Facility Type is Associated with Margin Status, Use of Lymphadenectomy and Overall Survival.

Authors:  Lu Wu; Diamantis I Tsilimigras; Anghela Z Paredes; Rittal Mehta; J Madison Hyer; Katiuscha Merath; Kota Sahara; Fabio Bagante; Eliza W Beal; Feng Shen; Timothy M Pawlik
Journal:  World J Surg       Date:  2019-07       Impact factor: 3.352

2.  Role of Lymph Node Dissection in Small (≤ 3 cm) Intrahepatic Cholangiocarcinoma.

Authors:  Andrea Ruzzenente; Simone Conci; Luca Viganò; Giorgio Ercolani; Serena Manfreda; Fabio Bagante; Andrea Ciangherotti; Corrado Pedrazzani; Antonio D Pinna; Calogero Iacono; Guido Torzilli; Alfredo Guglielmi
Journal:  J Gastrointest Surg       Date:  2019-02-28       Impact factor: 3.452

3.  A Multi-institutional International Analysis of Textbook Outcomes Among Patients Undergoing Curative-Intent Resection of Intrahepatic Cholangiocarcinoma.

Authors:  Katiuscha Merath; Qinyu Chen; Fabio Bagante; Sorin Alexandrescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Matthew J Weiss; Todd W Bauer; Feng Shen; George A Poultsides; Olivier Soubrane; Guillaume Martel; B Groot Koerkamp; Alfredo Guglielmi; Endo Itaru; Jordan M Cloyd; Timothy M Pawlik
Journal:  JAMA Surg       Date:  2019-06-19       Impact factor: 14.766

4.  A radiomics approach to predict lymph node metastasis and clinical outcome of intrahepatic cholangiocarcinoma.

Authors:  Gu-Wei Ji; Fei-Peng Zhu; Yu-Dong Zhang; Xi-Sheng Liu; Fei-Yun Wu; Ke Wang; Yong-Xiang Xia; Yao-Dong Zhang; Wang-Jie Jiang; Xiang-Cheng Li; Xue-Hao Wang
Journal:  Eur Radiol       Date:  2019-03-26       Impact factor: 5.315

5.  Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma.

Authors:  Shoji Kubo; Hiroji Shinkawa; Yoshinari Asaoka; Tatsuya Ioka; Hiroshi Igaki; Namiki Izumi; Takao Itoi; Michiaki Unno; Masayuki Ohtsuka; Takuji Okusaka; Masumi Kadoya; Masatoshi Kudo; Takashi Kumada; Norihiro Kokudo; Michiie Sakamoto; Yoshihiro Sakamoto; Hideyuki Sakurai; Tadatoshi Takayama; Osamu Nakashima; Yasushi Nagata; Etsuro Hatano; Kenichi Harada; Takamichi Murakami; Masakazu Yamamoto
Journal:  Liver Cancer       Date:  2022-02-23       Impact factor: 12.430

Review 6.  The focus clinical research in intrahepatic cholangiocarcinoma.

Authors:  Yinghui Song; Mengting Cai; Yuhang Li; Sulai Liu
Journal:  Eur J Med Res       Date:  2022-07-11       Impact factor: 4.981

Review 7.  Meta-analysis of laparoscopic versus open liver resection for intrahepatic cholangiocarcinoma.

Authors:  Nikolaos Machairas; Ioannis D Kostakis; Dimitrios Schizas; Stylianos Kykalos; Nikolaos Nikiteas; Georgios C Sotiropoulos
Journal:  Updates Surg       Date:  2020-11-21

Review 8.  Resection for intrahepatic cholangiocellular cancer: new advances.

Authors:  Daniel R Waisberg; Rafael S Pinheiro; Lucas S Nacif; Vinicius Rocha-Santos; Rodrigo B Martino; Rubens M Arantes; Liliana Ducatti; Quirino Lai; Wellington Andraus; Luiz C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-12

9.  Impact of lymph node dissection on clinical outcomes of intrahepatic cholangiocarcinoma: Inverse probability of treatment weighting with survival analysis.

Authors:  Yuzo Umeda; Toshiharu Mitsuhashi; Toru Kojima; Daisuke Satoh; Kenta Sui; Yoshikatsu Endo; Masaru Inagaki; Masahiro Oishi; Takahito Yagi; Toshiyoshi Fujiwara
Journal:  J Hepatobiliary Pancreat Sci       Date:  2021-09-16       Impact factor: 3.149

Review 10.  The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma.

Authors:  Guergana Panayotova; Jarot Guerra; James V Guarrera; Keri E Lunsford
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.